Use of Zoledronic Acid in a Neonate with Subcutaneous Fat Necrosis Complicated with Severe, Refractory Hypercalcemia
25 June 2019 (online)
Objective Subcutaneous fat necrosis (SCFN) is a rare condition that may occur in the neonatal period. SCFN is an inflammatory disorder of the adipose tissue, usually found in full-term healthy infants who have a history of intrauterine or perinatal distress. It is usually a self-limited condition; however, in some cases, it can get complicated, leading to severe hypercalcemia that may be life-threatening.
Study Design We report and describe a classic presentation of SCFN that led to severe hypercalcemia refractory to standard treatment. The diagnosis of SCFN was made based on the finding of subcutaneous nodules and of hypercalcemia. The serum calcium level reached 16.6 mg/dL. Hypercalcemia was treated first with intravenous infusions of fluids and furosemide and then of methylprednisolone. This standard treatment was not effective; therefore, we administered a single low dose of zoledronic acid, which, in turn, was efficacious in ultimately managing the hypercalcemia.
Conclusion Our case shows how a single low dose of zoledronic acid was safe and effective in managing severe hypercalcemia unresponsive to conventional treatment while minimizing the risk of hypocalcemic rebounds.
- 1 Mahé E, Girszyn N, Hadj-Rabia S, Bodemer C, Hamel-Teillac D, De Prost Y. Subcutaneous fat necrosis of the newborn: a systematic evaluation of risk factors, clinical manifestations, complications and outcome of 16 children. Br J Dermatol 2007; 156 (04) 709-715
- 2 Burden AD, Krafchik BR. Subcutaneous fat necrosis of the newborn: a review of 11 cases. Pediatr Dermatol 1999; 16 (05) 384-387
- 3 Lombardi G, Cabano R, Bollani L, Del Forno C, Stronati M. Effectiveness of pamidronate in severe neonatal hypercalcemia caused by subcutaneous fat necrosis: a case report. Eur J Pediatr 2009; 168 (05) 625-627
- 4 Tran JT, Sheth AP. Complications of subcutaneous fat necrosis of the newborn: a case report and review of the literature. Pediatr Dermatol 2003; 20 (03) 257-261
- 5 Aljaser F, Weinstein M. A 1-week-old newborn with hypercalcemia and palpable nodules: subcutaneous fat necrosis. CMAJ 2008; 178 (13) 1653-1654
- 6 Tuddenham E, Kumar A, Tarn A. Subcutaneous fat necrosis causing neonatal hypercalcaemia. BMJ Case Rep 2015; 2015: bcr2014208460
- 7 Di Bari JA, Nead JA, Schurman SJ. Zoledronic acid for neonatal subcutaneous fat necrosis. Clinical Case Reports 2017; 5 (05) 567-569
- 8 Stefanko NS, Drolet BA. Subcutaneous fat necrosis of the newborn and associated hypercalcemia: A systematic review of the literature. Pediatr Dermatol 2019; 36 (01) 24-30
- 9 Samedi VM, Yusuf K, Yee W, Obaid H, Al Awad EH. Neonatal hypercalcemia secondary to subcutaneous fat necrosis successfully treated with pamidronate: a case series and literature review. AJP Rep 2014; 4 (02) e93-e96
- 10 Alos N, Eugène D, Fillion M, Powell J, Kokta V, Chabot G. Pamidronate: Treatment for severe hypercalcemia in neonatal subcutaneous fat necrosis. Horm Res 2006; 65 (06) 289-294
- 11 Pérez Martínez E, Camprubí Camprubí M, Ramos Cebrián M. , et al. Treatment with bisphosphonates in severe hypercalcemia due to subcutaneous fat necrosis in an infant with hypoxic-ischemic encephalopathy. J Perinatol 2014; 34 (06) 492-493
- 12 Trullemans B, Bottu J, Van Nieuwenhuyse J-P. Etidronate per os in subcutaneous fat necrosis with hypercalcemia and nephrocalcinosis [in French]. Arch Pediatr 2007; 14 (02) 170-172
- 13 Rice AM, Rivkees SA. Etidronate therapy for hypercalcemia in subcutaneous fat necrosis of the newborn. J Pediatr 1999; 134 (03) 349-351
- 14 Munns CF, Rajab MH, Hong J. , et al. Acute phase response and mineral status following low dose intravenous zoledronic acid in children. Bone 2007; 41 (03) 366-370